Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 5
2004 3
2005 6
2006 9
2007 15
2008 10
2009 6
2010 17
2011 13
2012 11
2013 15
2014 11
2015 6
2016 1
2017 3
2018 2
2019 7
2020 2
2021 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Virus-like particles for vaccination against cancer.
Mohsen MO, Speiser DE, Knuth A, Bachmann MF. Mohsen MO, et al. Among authors: knuth a. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Jan;12(1):e1579. doi: 10.1002/wnan.1579. Epub 2019 Aug 27. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020. PMID: 31456339 Free PMC article. Review.
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie. Al-Batran SE, et al. Among authors: knuth a. J Clin Oncol. 2008 Mar 20;26(9):1435-42. doi: 10.1200/JCO.2007.13.9378. J Clin Oncol. 2008. PMID: 18349393 Clinical Trial.
Classification of current anticancer immunotherapies.
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. Galluzzi L, et al. Among authors: knuth a. Oncotarget. 2014 Dec 30;5(24):12472-508. doi: 10.18632/oncotarget.2998. Oncotarget. 2014. PMID: 25537519 Free PMC article. Review.
HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells.
Zecher BF, Ellinghaus D, Schloer S, Niehrs A, Padoan B, Baumdick ME, Yuki Y, Martin MP, Glow D, Schröder-Schwarz J, Niersch J, Brias S, Müller LM, Habermann R, Kretschmer P, Früh T, Dänekas J, Wehmeyer MH, Poch T, Sebode M; International PSC Study Group (IPSCSG); Ellinghaus E, Degenhardt F, Körner C, Hoelzemer A, Fehse B, Oldhafer KJ, Schumacher U, Sauter G, Carrington M, Franke A, Bunders MJ, Schramm C, Altfeld M. Zecher BF, et al. Gut. 2024 Jan 5;73(2):325-337. doi: 10.1136/gutjnl-2023-329524. Gut. 2024. PMID: 37788895 Free PMC article.
Developments in cancer immunotherapy.
van den Broek M, von Boehmer L, Knuth A. van den Broek M, et al. Among authors: knuth a. Dig Dis. 2010;28(1):51-6. doi: 10.1159/000282064. Epub 2010 May 7. Dig Dis. 2010. PMID: 20460890 Free article. Review.
Clinical cancer vaccine trials.
Jäger E, Jäger D, Knuth A. Jäger E, et al. Among authors: knuth a. Curr Opin Immunol. 2002 Apr;14(2):178-82. doi: 10.1016/s0952-7915(02)00318-7. Curr Opin Immunol. 2002. PMID: 11869889 Review.
Antigen-specific immunotherapy and cancer vaccines.
Jäger E, Jäger D, Knuth A. Jäger E, et al. Among authors: knuth a. Int J Cancer. 2003 Oct 10;106(6):817-20. doi: 10.1002/ijc.11292. Int J Cancer. 2003. PMID: 12918057 Free article. Review.
Antibodies and vaccines--hope or illusion?
Jäger D, Knuth A. Jäger D, et al. Among authors: knuth a. Breast. 2005 Dec;14(6):631-5. doi: 10.1016/j.breast.2005.08.029. Epub 2005 Oct 20. Breast. 2005. PMID: 16242931 Review.
NY-ESO-1: review of an immunogenic tumor antigen.
Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, Knuth A, Chen YT, Old LJ. Gnjatic S, et al. Among authors: knuth a. Adv Cancer Res. 2006;95:1-30. doi: 10.1016/S0065-230X(06)95001-5. Adv Cancer Res. 2006. PMID: 16860654 Review.
140 results